Coeur Mining (CDE) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items. While Coeur Mining has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings ou ...

Group 1 - Kodiak Gas Services reported quarterly earnings of $0.42 per share, exceeding the Zacks Consensus Estimate of $0.39 per share, and showing an increase from $0.39 per share a year ago, representing an earnings surprise of 7.69% [1] - The company achieved revenues of $329.64 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.06%, and up from $215.49 million year-over-year [2] - Kodiak Gas has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates two times in the same period [2] Group 2 - The stock has underperformed, losing about 16.2% since the beginning of the year, compared to the S&P 500's decline of 4.7% [3] - The current consensus EPS estimate for the upcoming quarter is $0.40 on revenues of $336.17 million, and for the current fiscal year, it is $2.09 on revenues of $1.35 billion [7] - The Zacks Industry Rank for Oil and Gas - Mechanical and Equipment is currently in the bottom 15% of over 250 Zacks industries, indicating potential challenges for stock performance [8] Group 3 - The estimate revisions trend for Kodiak Gas is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The outlook for the industry can significantly impact stock performance, with the top 50% of Zacks-ranked industries outperforming the bottom 50% by more than 2 to 1 [8]

Group 1 - AerSale Corporation reported a quarterly loss of $0.05 per share, missing the Zacks Consensus Estimate of $0.13, and compared to earnings of $0.11 per share a year ago, representing an earnings surprise of -138.46% [1] - The company posted revenues of $65.78 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 25.31%, and down from year-ago revenues of $90.54 million [2] - Over the last four quarters, AerSale has surpassed consensus EPS estimates just once and topped consensus revenue estimates only once [2] Group 2 - AerSale shares have increased by approximately 11.8% since the beginning of the year, contrasting with the S&P 500's decline of -4.7% [3] - The company's earnings outlook is crucial for investors, including current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for AerSale is currently favorable, resulting in a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6] Group 3 - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $84.34 million, and for the current fiscal year, it is $0.70 on revenues of $368.49 million [7] - The Aerospace - Defense Equipment industry is currently ranked in the top 14% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]

Veracyte (VCYT) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of 55%. A quarter ago, it was expected that this molecular diagnostic company would post earnings of $0.29 per share when it actually produced earnings of $0.36, delivering a surprise of 24.14%. Over the last four quarters, th ...

Core Insights - Evolus, Inc. reported a quarterly loss of $0.18 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.10, marking an earnings surprise of -80% [1] - The company's revenues for the quarter ended March 2025 were $68.52 million, missing the Zacks Consensus Estimate by 4.83%, but showing an increase from $59.33 million year-over-year [2] - Evolus has not surpassed consensus EPS estimates over the last four quarters and has only topped revenue estimates once in that same period [2] Company Performance - Evolus shares have increased by approximately 5.2% since the beginning of the year, contrasting with a -4.7% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $82.86 million, and for the current fiscal year, it is -$0.01 on revenues of $351.43 million [7] Earnings Outlook - The estimate revisions trend for Evolus is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] - The outlook for the Medical - Products industry, to which Evolus belongs, is in the bottom 28% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Core Viewpoint - GoodRx Holdings, Inc. reported quarterly earnings of $0.09 per share, matching the Zacks Consensus Estimate, and showing an increase from $0.08 per share a year ago [1] - The company posted revenues of $202.97 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 0.19% and up from $197.88 million year-over-year [2] Financial Performance - GoodRx's earnings have not surpassed consensus EPS estimates over the last four quarters [1] - The company has topped consensus revenue estimates only once in the past four quarters [2] - The current consensus EPS estimate for the upcoming quarter is $0.10 on revenues of $205.65 million, and for the current fiscal year, it is $0.40 on revenues of $824.14 million [7] Market Performance - GoodRx shares have declined approximately 8.4% since the beginning of the year, compared to a 4.7% decline in the S&P 500 [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations of outperforming the market in the near future [6] Industry Outlook - The Medical Services industry, to which GoodRx belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact GoodRx's stock performance [5]

Cardlytics (CDLX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 22.22%. A quarter ago, it was expected that this company would post a loss of $0.24 per share when it actually produced break-even earnings, delivering a surprise of 100%.Over the last four quarters, the company has surpassed c ...

Goodyear (GT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this tire maker would post earnings of $0.39 per share when it actually produced earnings of $0.39, delivering no surprise.Over the last four quarters, the company has surpassed conse ...

Company Performance - Airgain reported a quarterly loss of $0.11 per share, which aligns with the Zacks Consensus Estimate, compared to a loss of $0.08 per share a year ago [1] - The company posted revenues of $12.01 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 0.72%, and down from $14.23 million year-over-year [2] - Over the last four quarters, Airgain has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2][3] Stock Movement and Outlook - Airgain shares have declined approximately 43.3% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at -$0.06 for the coming quarter and -$0.05 for the current fiscal year [4][7] - The estimate revisions trend for Airgain is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Communication - Components industry, to which Airgain belongs, is currently ranked in the bottom 17% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Airgain's stock performance [5]

Core Insights - Nuvation Bio Inc. reported a quarterly loss of $0.16 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.07 per share a year ago [1] - The company generated revenues of $3.08 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 23.36%, while revenues were zero a year ago [2] - Nuvation Bio's shares have declined approximately 21.4% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] Earnings Outlook - The earnings outlook for Nuvation Bio is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.18 on revenues of $2.5 million, and for the current fiscal year at -$0.69 on revenues of $15 million [7] - The company's earnings outlook will significantly depend on management's commentary during the earnings call [2] Industry Context - The Medical - Biomedical and Genetics industry, to which Nuvation Bio belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Nuvation Bio's stock performance [5]